Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
Standard
Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients. / Riethdorf, Sabine; Hoegel, Bernhard; John, Birgit; Ott, German; Fritz, Peter; Thon, Susanne; Löning, Thomas; Pantel, Klaus.
In: J CANCER RES CLIN, Vol. 137, No. 2, 2, 2011, p. 261-269.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
AU - Riethdorf, Sabine
AU - Hoegel, Bernhard
AU - John, Birgit
AU - Ott, German
AU - Fritz, Peter
AU - Thon, Susanne
AU - Löning, Thomas
AU - Pantel, Klaus
PY - 2011
Y1 - 2011
N2 - As HER2 status is a strong predictor of the response to trastuzumab, clinical guidelines recommend that all breast tumours are first evaluated for HER2 protein expression by immunohistochemistry (IHC) followed by confirmatory testing for HER2 gene amplification using fluorescence in situ hybridisation (FISH) for 2+ cases. Alternatively, chromogenic in situ hybridisation (CISH) offers a simpler, less expensive approach to detect HER2 amplification.
AB - As HER2 status is a strong predictor of the response to trastuzumab, clinical guidelines recommend that all breast tumours are first evaluated for HER2 protein expression by immunohistochemistry (IHC) followed by confirmatory testing for HER2 gene amplification using fluorescence in situ hybridisation (FISH) for 2+ cases. Alternatively, chromogenic in situ hybridisation (CISH) offers a simpler, less expensive approach to detect HER2 amplification.
M3 - SCORING: Journal article
VL - 137
SP - 261
EP - 269
JO - J CANCER RES CLIN
JF - J CANCER RES CLIN
SN - 0171-5216
IS - 2
M1 - 2
ER -